Table 2.

Baseline characteristics of patients in Swiss ACS Cohort stratified according to trimethyllysine tertiles

Characteristics	All patients (N = 1683)	Tertile 1 (N = 556) <0.56 µM	Tertile 2 (N = 567) 0.56–0.73 µM	Tertile 3 (N = 560) >0.73 µM	P-value
Age (years)	63.9 ± 12.4	61.5 ± 11.6	62.4 ± 12.3	68.0 ± 12.4	<0.001
Male (%)	77.8	65.3	83.4	84.5	<0.001
C-reactive protein (mg/dL)	2.8 (1.1–8.0)	2.5 (1.08–6.03)	2.4 (1.08–6.93)	3.6 (1.4–12.5)	<0.001
History of hyperlipidaemia (%)	62.6	62.9	59.6	65.4	0.14
History of diabetes (%)	17.5	13.8	15.3	23.2	<0.001
History of hypertension (%)	59.3	52.7	56.3	68.9	<0.001
History of revascularization (%)	17.4	14.7	15.2	22.3	0.001
History of CAD (%)	36.8	37.2	37.6	35.6	0.77
History of smoking (%)	67.8	69.1	69.3	65.0	0.22
HDL-C (mg/dL)	43.3 (36.3–53.4)	46.4 (37.9–55.7)	43.3 (35.6–53.0)	42.2 (35.6–51.0)	<0.001
LDL-C (mg/dL)	118.7 (90.1–148.5)	125.3 (94.7–154.7)	121.4 (95.9–150.8)	108.7 (80.8–136.9)	<0.001
TMAO (µM)	2.87 (1.94–4.85)	2.29 (1.59–3.26)	2.60 (1.90–3.94)	4.35 (2.82–7.17)	<0.001
Hs-TnT (µg/L)	0.20 (0.06–0.71)	0.18 (0.05–0.54)	0.20 (0.06–0.7)	0.24 (0.06–0.93)	0.005
TML (µM)	0.64 (0.52–0.81)	0.48 (0.42–0.52)	0.64 (0.60–0.69)	0.90 (0.81–1.09)	<0.001
eGFR (mL/min/1.73 m2)	100.2 (74.2–126.9)	112.7 (90.3–137.9)	103.8 (83.7–129.1)	77.4 (54.5–105.9)	<0.001
Baseline medications (%)
Aspirin (%)	33.3	26.8	30.9	42.4	<0.001
ACE inhibitors (%)	18.3	16.1	14.8	24.0	<0.001
Statin (%)	31.4	28.4	30.0	35.8	0.02
Beta-blockers (%)	26.3	21.4	23.9	33.8	<0.001

Continuous data are presented as mean ± standard deviation or median (interquartile range), and categorical variables are presented as %. One-way ANOVA or Kruskal–Wallis test were used for numeric data comparison. The χ² test was used for categorical data.